DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $525

Oppenheimer maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $450 to $525.

Benzinga · 03/11/2020 12:47

Oppenheimer maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $450 to $525.